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A b s t r a c t
Introduction: Rotavirus is the main etiological cause of intestinal infections 
in children. Voluntary rotavirus vaccines were included in the Polish vac-
cination schedule in 2007. The aim of this study was to assess the effec-
tiveness of a  completed rotavirus vaccination course in preventing acute 
gastroenteritis in Polish infants during their first five years of life.
Material and methods: This was a  retrospective cohort study conducted 
in Lesser Poland (Malopolska Province). The sample population included 
a group of 303 children who received the completed rotavirus vaccination 
course and 303 children not vaccinated against rotavirus. The date of the 
child’s acute gastroenteritis diagnosis and his or her vaccination history 
were extracted from the physicians’ records. Each kind of diagnosed acute 
gastroenteritis during winter-spring rotavirus seasons was treated as the 
endpoint. The relative risk of having gastrointestinal infection was assessed 
using the hazard ratio from the Cox proportional hazards regression model. 
Results: In the examined group, 96 (15.8%) children had winter-spring gas-
trointestinal infections. In the non-vaccinated children, the cumulative inci-
dence of these infections in the first 5 years of life was 20.8%, whereas in 
the children vaccinated with Rotarix it was only 10.9%. Those who were vac-
cinated with Rotarix had a 44% reduction in the risk of a winter-spring acute 
gastroenteritis infection compared to those not vaccinated with Rotarix 
(p = 0.005). Birth weight less than 2500 g increased the risk of the infection 
twofold and also reached statistical significance (p = 0.044).
Conclusions: The results showed that Rotarix is effective in preventing acute 
gastroenteritis in Polish children during rotavirus seasons.
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Introduction
Rotavirus is the leading cause of severe pediatric gastroenteritis [1, 2]. 
The rotavirus vaccines (Rotarix and RotaTeq) were licensed and recom-
mended for routine immunization in the European Union in 2006 [3]. The 
results of a pre-licensure trial suggest very high efficacy of both vaccines 
in preventing rotavirus gastroenteritis [4–7]. Nevertheless, the effective-
ness of vaccination in practice differs from the efficacy observed in the 
ideal conditions of a clinical trial. Furthermore, the vaccines are indicat-
ed for the prevention of rotavirus gastroenteritis caused by certain virus 
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serotypes which are not distributed in the same 
range in different populations [8, 9]. Apart from 
the host factors, it could be an important reason 
for higher vaccine efficacy in developed countries 
compared with developing ones. The efficacy of 
both vaccines has ranged from 80% to 98% in in-
dustrialized countries and in Latin America, but in 
countries such as Kenya and Malawi in Africa and 
Bangladesh and Vietnam in Asia the efficacy was 
lower, ranging from 51% to 64% [10–15].
Before introduction of the rotavirus vaccine in 
2007, rotavirus was a leading etiological agent of 
severe gastroenteritis in young children in Poland 
[16]. Incidence rates of viral gastroenteritis in the 
entire population in 2007–2012 were estimated 
between 57.6 and 116.6 per 100  000, while in 
children up to the 2nd year of life these were be-
tween 1371.7 and 2288.4 per 100 000. Both in the 
entire population and in the children up to the age 
of 2, rates presented an increasing trend. A similar 
trend was observed in the incidence of rotavirus 
gastroenteritis in the entire population, with val-
ues from 39.9 to 79.9 per 100 000 [17–19]. 
We use both rotavirus vaccines (Rotarix and 
RotaTeq) simultaneously, according to the nation-
al immunization program, as a  voluntary option 
which requires that parents spend extra money for 
their children’s vaccination, so not many infants 
have been vaccinated yet (annually less than 20% 
of the population up to the 12th month of life). The 
two vaccines differ greatly in their conception and 
expression of rotavirus strains. Rotarix is a human 
monovalent vaccine and RotaTeq is a bovine-hu-
man pentavalent vaccine [20, 21]. Furthermore, 
there are no reliable data with respect to the dom-
inant rotavirus serotype in our population. This sit-
uation is a reason for raising a question about the 
effectiveness of rotavirus vaccination in Poland.
The aim of the study was to assess the ef-
fectiveness of a  completed rotavirus vaccination 
course in preventing acute gastroenteritis during 
rotavirus seasons in Polish infants during the first 
5 years of their life. 
Material and methods
This was a retrospective cohort study.
Study population
Subjects were identified using physicians’ re-
cords in the Lesser Poland (Malopolska) Province 
in Poland. All children who met the inclusion cri-
teria in randomly selected general practices and 
whose parent signed the consent were included in 
the study cohort. There was not a sufficient num-
ber of infants vaccinated with RotaTeq to achieve 
any conclusive results with respect to this vaccine, 
so we limited our analysis to the effectiveness of 
Rotarix. The sample population of this study in-
cluded 2 cohorts, 303 children in each. One group 
received a  complete Rotarix (manufactured by 
GlaxoSmithKline Biologicals S.A., Rue de l’Institut 
89, B-1330 Rixensart, Belgium) course – 2 doses 
concurrently with other vaccines according to the 
immunization schedule. The vaccine was admin-
istered to infants aged 6 weeks up to 24 weeks 
of life. The minimal interval between the first 
and the second dose of Rotarix was 4 weeks. The 
control group received other vaccines, but not the 
rotavirus vaccine, through the period 2007–2012. 
The infants in the non-vaccinated cohort derived 
from the same physicians’ practice as the vacci-
nated group. Infants vaccinated with long delays 
or those who did not obtain 2 doses of Rotarix 
vaccine were excluded from the study population. 
The study was approved by the Jagiellonian 
University Ethical Committee (Krakow, Poland).
Gastroenteritis diagnosis and vaccination 
history 
The date of the child’s acute gastroenteritis 
diagnosis and his or her vaccination history were 
extracted directly from the physician’s records. 
The definition of acute gastroenteritis was based 
on physician’s diagnosis, ICD-10 code: A02.0, A04, 
A05, A08, A09. In our cohort there were not many 
cases with the determined etiology of acute gas-
troenteritis. We counted as the endpoint each kind 
of diagnosed acute gastroenteritis (with deter-
mined and undetermined etiology) if it occurred 
during winter-spring rotavirus seasons (December 
to May in 2007–2012). The choice of rotavirus 
season was based on the proportion of reported 
cases of rotavirus gastroenteritis in the total re-
ported cases of gastroenteritis (A02.0, A04, A05, 
A08, A09) in the entire population, calculated from 
biweekly reports on cases of infectious diseases 
and poisonings in Poland published by the Nation-
al Institute of Public Health – National Institute of 
Hygiene [22]. In the studied period an increased 
proportion (about 40%) was observed in the win-
ter-spring season (December to May) compared to 
the summer-autumn season (June to November) 
(about 20%). Only about 30% of all viral gastro-
enteritis (A08) cases occurred outside the rotavi-
rus season in Poland. The same proportion was 
observed according to rotavirus infections. Taking 
into account all acute gastroenteritis (A02.0, A04, 
A05, A08, A09) cases, about 45% of them occurred 
outside the rotavirus season [22].
Some additional information about the med-
ical condition of infants that could potentially 
influence vaccine effectiveness and the risk of 
gastrointestinal infection, such as gestational age, 
Apgar score, birth weight and length, neonatal in-
fections, congenital malformations and communi-
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cable diseases in infancy, were also extracted from 
the medical records.
Questionnaire for the parents of infants
Mothers were interviewed by trained nurses 
using a standardized questionnaire. Questions in-
cluded information about prenatal and postnatal 
development, birth order, feeding mode, family 
size and parents’ education.
Statistical analysis
Episodes of acute gastroenteritis were included 
to analyze whether they occurred in the vaccinat-
ed infants at least 14 days after receiving the com-
plete vaccination course (second dose of Rotarix). 
This length of time is essential to reach a  suffi-
cient immunological response to such a vaccine. In 
controls, gastrointestinal infections were included 
in the analysis if they took place after 122 days of 
life (108 days, as the median of the second dose 
administration in the vaccinated group + 14 days 
for the immunological response). 
The relative risk of having a gastrointestinal in-
fection during the first 5 years of life was assessed 
using the hazard ratio (HR) with 95% confidence 
intervals (CI) from the Cox proportional hazards 
regression model. Variables such as age, paren-
tal education (university vs. secondary or lower), 
place of living, breastfeeding (< 6 months vs. 
≥ 6 months), birth weight (< 2500 g) and presence 
of other children in the family were taken into 
consideration as potential confounders. Vaccine 
effectiveness was calculated as: (1 – HR) × 100. 
Analyses were performed using STATA 12.1 soft-
ware.
Results
The study population consisted of 303 chil-
dren vaccinated with Rotarix and 303 controls, 
mean age 2.7 ±1.2 years (range from 3 months to 
6 years), 50.8% boys and 49.2% girls (Table I). Mean 
age differed by 2 months between the non-vacci-
nated and Rotarix vaccinated group. Parents of the 
children vaccinated against rotaviruses were bet-
ter educated than parents of the non-vaccinated 
ones: the percentage of mothers with a university 
degree was 56.3% vs. 40.0%, fathers: 33.4% vs. 
22.3% respectively. This fact represented a  sta-
tistically significant difference. Children from the 
vaccinated group less often had siblings (53.0% vs. 
64.0%, p < 0.007) and more often lived in a big city 
(9.6% vs. 2.0%, p < 0.001). The examined groups 
did not differ significantly either in birth weight or 
in percentage of breastfed children. 
Among the examined group, 95 (15.7%) chil-
dren suffered from winter-spring gastrointestinal 
infections. In the non-vaccinated children, the cu-
mulative incidence in the first five years of life was 
20.5%, whereas in those vaccinated with Rotarix 
it was only 10.9% (p = 0.001). Figure 1 presents 
Kaplan-Meier curves of acute gastroenteritis inci-
dence during the 5-year period in the vaccinated 
and non-vaccinated group. The Rotarix vaccinated 
children had significantly better survival (log-rank 
test, p = 0.0053).
The univariate Cox model-based survival anal-
ysis showed that among considered factors, only 
Rotarix vaccine and low birth weight were signif-
icant predictors of gastrointestinal infection. Ro-
tarix vaccine had a  significant protective effect. 
Among the children vaccinated with Rotarix, the 
risk of developing acute gastroenteritis in the win-
ter-spring season during their first 5 years of life 
was lower by 44% compared to the non-vaccinat-
ed population (p = 0.005). Birth weight less than 
2500 g increased the risk of infection twofold and 
also reached statistical significance (p = 0.047). 
Other variables defined as potential confounders 
did not influence vaccine effectiveness. The two 
variables birth weight and vaccination with Rotar-
ix were taken into the multivariate model. After 
this adjustment, the proportional hazard ratio 
for vaccination with Rotarix and low birth weight 
did not change substantially and remained sta-
tistically significant (Table II). A  similar analysis 
was conducted separately for the first 1, 2, 3 and 
4 years of life (Table III). The effect of Rotarix was 
significant except for the first year of life, which is 
probably a  consequence of the small number of 
cases and the short period of follow-up. From the 
second year of life the vaccine effectiveness be-
came significant.
Discussion
Our findings demonstrate the influence of an 
effective rotavirus vaccine in preventing acute 
gastroenteritis among Polish children. In our study 
cohort the effectiveness of a  full 2-dose Rotarix 
course over five winter-spring rotavirus seasons in 
children up to the 2nd, 3rd, 4th and 5th year of life was 
high and ranged from 42.5 to 45.5. During non-ro-
tavirus seasons the vaccine demonstrated some 
effectiveness against all-cause gastroenteritis, al-
though it was not significant. This vaccine’s effec-
tiveness in non-rotavirus seasons could be due to 
rotavirus cases that occurred outside the winter 
seasons or perhaps because of the cross-protec-
tion against other enteric viruses, although the 
mechanism of this effect is unknown [23].
The assumption of the winter-spring rotavirus 
season from December to May is consistent with 
the results of previous studies conducted in coun-
tries from a similar climate zone [24] and Polish 
surveillance data related to control of rotavirus 
infections [22]. High rotavirus vaccination cover-
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age in infants is likely to postpone and shorten 
the rotavirus season [25]. We have not seen such 
influence on the Polish epidemiological situation 
of rotavirus gastroenteritis yet, because vaccina-
tion coverage against rotavirus infections is still 
very low. At the beginning of vaccine availability 
in Poland in 2007, only 3% of infants were vac-
cinated against rotavirus infection. A  gradually 
rising trend reached the rate of 20% in 2011 and 
then it started to decrease from 2012. Low vac-
cination coverage has a  weak influence on herd 
immunity against rotavirus infection in the popu-
lation. Therefore, in our cohort study, the rotavirus 
vaccine effectiveness in preventing acute gastro-
enteritis could be higher than in populations with 
high vaccination coverage. The small number of 
Table I. Characteristics of participants stratified by children vaccinated and not vaccinated against rotavirus
Parameter Number and percentage of children P-value
Non-vaccinated
(N = 303) 
Vaccinated with 
Rotarix (N = 303)
N % N %
Gender Male 154 50.8 154 50.8 NS
Female 149 49.2 149 49.2
Living place Rural area 179 59.1 169 55.8 < 0.001
Small city 118 38.9 105 34.6
Big city (> 100 000 inhabitants) 6 2.0 29 9.6
Pregnancy Single 294 97.0 301 99.3 0.063
Multiple 9 3.0 2 0.7
Mother’s 
education
Elementary 9 3.0 0 – < 0.001
Vocational 50 16.6 29 9.7
Higher 122 40.4 102 34.0
University 121 40.0 169 56.3
Father’s 
education
Elementary 12 4.0 9 3.0 0.002
Vocational 107 35.7 64 21.4
Higher 114 38.0 126 42.2
University 67 22.3 100 33.4
Other children in the family 194 64.0 160 53.0 0.007
Number of 
children 
living in the 
same flat 
1 136 69.4 129 80.1 0.022
2 39 19.9 26 16.2
3 15 7.6 6 3.7
4 or more  6 3.1 0 0.0
Siblings vaccinated against rotaviruses 8 3.8 49 31.8 < 0.001
Birth weight < 2500 g 14 4.6 10 3.4 NS
Breast 
feeding
No 23 7.9 23 7.8 NS
≤ 6 months 109 30.8 91 31.1
> 6 months 160 61.3 179 61.1
Age, mean ± SD [years] 2.86 ±1.22 2.63 ±1.09 0.010
 0 1 2 3 4 5
           Time of life [years]
            Non-vaccinated         Rotarix         
Figure 1. Kaplan-Meier curves of acute gastro-
enteritis incidence during the 5-year period in the 
vaccinated and non-vaccinated group
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vaccinated infants did not significantly decrease 
the risk of being infected by rotavirus for another 
population; thus the gastroenteritis incidence in 
the unvaccinated cohort could be higher than in 
a population with the effect of herd immunity. This 
is one reason why it is difficult to compare our 
results with the previous studies, because mostly 
they were related to populations with higher ro-
tavirus vaccination coverage than the Polish chil-
dren [26].
In the previous papers related to rotavirus 
vaccine effectiveness in preventing acute gastro-
enteritis, the analysis was conducted for hospital-
ized and outpatient cases separately, with the ef-
fectiveness of 47% and 15%, respectively (results 
concerning RotaTeq) [27]. Our results calculated 
hospitalized and outpatient cases together rev-
aled the effectiveness about 45%. Similar effec-
tiveness as in Poland was obtained for Rotarix in 
the Israeli population – 50% in preventing acute 
gastroenteritis requiring a  physician’s visit [28]. 
The findings of our study cannot be compared 
with most of the other reports because they were 
mainly related to direct effectiveness of rotavirus 
vaccines in preventing rotavirus gastroenteritis 
[29–32]. In our study population, there was not 
a  sufficient number of etiologically confirmed 
gastroenteritis cases, and the reliability of labo-
ratory confirmation was rather poor. Therefore, 
we decided to include in our analysis the hospital 
admissions and outpatient visits due to all-cause 
acute gastroenteritis. That limitation did not al-
low us to determine the real vaccine effectiveness 
against rotavirus infections but only the indirect 
influence of the effectiveness on preventing all-
cause gastroenteritis in children during five rota-
virus seasons. Despite having no data on domi-
nant rotavirus serotypes and no reliable data on 
the burden of rotavirus infections in children, our 
findings suggest high health benefits of rotavirus 
vaccination in Poland.
The long period of follow-up, through five 
winter-spring rotavirus seasons, is a  strength of 
our study. We revealed the vaccine effectiveness 
during several seasons, despite the potential 
changeability of dominant rotavirus serotypes in 
Table II. Relative risk of wintertime gastrointestinal infections during the first five years of life in children vacci-
nated against rotaviruses
Variable HR 95% CI P-value
Univariate analysis:
Rotarix vaccination 0.56 0.36–0.85 0.007
Birth weight < 2500 g 2.21 1.02–4.77 0.044
Breast feeding ≤ 6 months 1.32 0.55–3.15 NS
Breast feeding > 6 months 1.10 0.47–2.56 NS
Mother’s education (higher or university) 0.90 0.52–1.57 NS
Father’s education (higher or university) 0.79 0.52–1.20 NS
Other children in the family 0.88 0.58–1.32 NS
Age 0.91 0.73–1.14 NS
Multivariate analysis:
Vaccination 0.56 0.37–0.86 0.008
Birth weight < 2500 g 2.23 1.03–4.82 0.041
Cox proportional hazards regression model: HR – hazard ratio, CI – confidence interval.
Table III. Relative risk of wintertime gastrointestinal infections in children vaccinated against rotaviruses
P-value HR (95% CI) Effectiveness (95% CI)
In the first year of life NS 0.67 (0.34–1.32) 32.9 (–32.2–65.9) 
In the first 2 years of life 0.022 0.57 (0.36–0.92) 42.5 (7.5–64.3)
In the first 3 years of life 0.012 0.56 (0.36–0.88) 43.7 (11.8–64.0)
In the first 4 years of life 0.006 0.55 (0.35–0.84) 45.5 (16.1–64.5)
In the first 5 years of life 0.007 0.56 (0.36–0.85) 44.3 (14.8–63.5)
Cox proportional hazards regression model: HR – hazard ratio, CI – confidence interval.
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the relatively long period of time [9]. Furthermore, 
we obtained similar vaccine effectiveness not only 
in infants up to the 2nd year (as in many previous 
studies) but also in children up to the 4th year of 
life. This is the first study related to rotavirus vac-
cine effectiveness in an Eastern European country. 
We were able to include in our analysis many po-
tentially confounding factors known to be associ-
ated with vaccine effectiveness and the increased 
risk of gastrointestinal infections [33, 34].
The limitation of the study is the exclusion from 
the analysis of infants vaccinated with RotaTeq. 
The small number of infants did not allow any con-
clusive results to be obtained with respect to this 
vaccine’s effectiveness. On the other hand, our co-
hort study allowed us to reveal the high effective-
ness of Rotarix in preventing acute gastroenteritis 
in children. This is more important information for 
us because more than 90% of infants vaccinated 
in Poland were administered this vaccine. 
In conclusion, our findings show that Rotarix is 
highly effective in preventing acute gastroenteritis 
during rotavirus seasons in Polish children. 
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